Achilles Therapeutics Q2 EPS $(0.42), Inline; Cash Position Of $144M Supports Operations Through 2025
Portfolio Pulse from Benzinga Newsdesk
Achilles Therapeutics reported Q2 losses of $(0.42) per share, in line with analyst consensus. This is a 4.55% increase over losses from the same period last year. The company's cash position of $144M is expected to support operations through 2025.
August 04, 2023 | 3:07 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Achilles Therapeutics' Q2 results met analyst expectations, with losses of $(0.42) per share. The company's strong cash position is expected to support operations through 2025.
Achilles Therapeutics' Q2 results were in line with analyst expectations, which is generally a neutral signal for the stock. The company's strong cash position, which is expected to support operations through 2025, is a positive signal as it reduces financial risk. However, the company is still reporting losses, which could put downward pressure on the stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100